A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model.

MLA

Phares, Timothy W., et al. “A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model.” Frontiers in Immunology, vol. 11, July 2020, p. 1377. EBSCOhost, https://doi.org/10.3389/fimmu.2020.01377.

APA

Phares, T. W., Kotraiah, V., Karunarathne, D. S., Huang, J., Browne, C. D., Buontempo, P., Mansour, M., Noe, A. R., Wykes, M. N., Pannucci, J., Tsuji, M., & Gutierrez, G. M. (2020). A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model. Frontiers in Immunology, 11, 1377. https://doi.org/10.3389/fimmu.2020.01377

Chicago

Phares, Timothy W, Vinayaka Kotraiah, Deshapriya S Karunarathne, Jing Huang, Cecille D Browne, Peter Buontempo, Marc Mansour, et al. 2020. “A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model.” Frontiers in Immunology 11 (July): 1377. doi:10.3389/fimmu.2020.01377.